Exact Mass: 523.1347890000001
Exact Mass Matches: 523.1347890000001
Found 140 metabolites which its exact mass value is equals to given mass value 523.1347890000001
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Deoxyribonucleic acid
Hapten
C26H26ClN5O3S (523.1444796000001)
Penfluridol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml[1][2][3][4].
PENFLURIDOL
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml[1][2][3][4].
Anhydropseudophlegmacin-9,10-quinone-3-amino-8-O-methyl ether
4-(hydroxymethyl)phenyl 5-O-nicotinyl-beta-D-apiofuranosyl(1->2)-beta-D-glucopyranoside|cucurbitoside L
Cys Asp Thr Trp
Cys Asp Trp Thr
Cys Glu Ser Trp
Cys Glu Trp Ser
Cys Ser Glu Trp
Cys Ser Trp Glu
Cys Thr Asp Trp
Cys Thr Trp Asp
Cys Trp Asp Thr
Cys Trp Glu Ser
Cys Trp Ser Glu
Cys Trp Thr Asp
Asp Cys Thr Trp
Asp Cys Trp Thr
Asp Met Met Gln
C19H33N5O8S2 (523.1770458000001)
Asp Met Gln Met
C19H33N5O8S2 (523.1770458000001)
Asp Gln Met Met
C19H33N5O8S2 (523.1770458000001)
Asp Thr Cys Trp
Asp Thr Trp Cys
Asp Trp Cys Thr
Asp Trp Thr Cys
Glu Cys Ser Trp
Glu Cys Trp Ser
Glu Met Met Asn
C19H33N5O8S2 (523.1770458000001)
Glu Met Asn Met
C19H33N5O8S2 (523.1770458000001)
Glu Asn Met Met
C19H33N5O8S2 (523.1770458000001)
Glu Ser Cys Trp
Glu Ser Trp Cys
Glu Trp Cys Ser
Glu Trp Ser Cys
Met Asp Met Gln
C19H33N5O8S2 (523.1770458000001)
Met Asp Gln Met
C19H33N5O8S2 (523.1770458000001)
Met Glu Met Asn
C19H33N5O8S2 (523.1770458000001)
Met Glu Asn Met
C19H33N5O8S2 (523.1770458000001)
Met Met Asp Gln
C19H33N5O8S2 (523.1770458000001)
Met Met Glu Asn
C19H33N5O8S2 (523.1770458000001)
Met Met Asn Glu
C19H33N5O8S2 (523.1770458000001)
Met Met Gln Asp
C19H33N5O8S2 (523.1770458000001)
Met Asn Glu Met
C19H33N5O8S2 (523.1770458000001)
Met Asn Met Glu
C19H33N5O8S2 (523.1770458000001)
Met Gln Asp Met
C19H33N5O8S2 (523.1770458000001)
Met Gln Met Asp
C19H33N5O8S2 (523.1770458000001)
Asn Glu Met Met
C19H33N5O8S2 (523.1770458000001)
Asn Met Glu Met
C19H33N5O8S2 (523.1770458000001)
Asn Met Met Glu
C19H33N5O8S2 (523.1770458000001)
Gln Asp Met Met
C19H33N5O8S2 (523.1770458000001)
Gln Met Asp Met
C19H33N5O8S2 (523.1770458000001)
Gln Met Met Asp
C19H33N5O8S2 (523.1770458000001)
Ser Cys Glu Trp
Ser Cys Trp Glu
Ser Glu Cys Trp
Ser Glu Trp Cys
Ser Trp Cys Glu
Ser Trp Glu Cys
Thr Cys Asp Trp
Thr Cys Trp Asp
Thr Asp Cys Trp
Thr Asp Trp Cys
Thr Trp Cys Asp
Thr Trp Asp Cys
Trp Cys Asp Thr
Trp Cys Glu Ser
Trp Cys Ser Glu
Trp Cys Thr Asp
Trp Asp Cys Thr
Trp Asp Thr Cys
Trp Glu Cys Ser
Trp Glu Ser Cys
Trp Ser Cys Glu
Trp Ser Glu Cys
Trp Thr Cys Asp
Trp Thr Asp Cys
KRP 203-phosphate
C24H27ClNO6PS (523.0985162000001)
8-chloro-11-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine,trihydrochloride
C26H29Cl4N3 (523.1115474000001)
N-(p-chlorophenyl)-2-cyano-2-[2,3-dihydro-3-[tetrahydro-2,4,6-trioxo-1-p-tolylpyrimidin-5(2H)-ylidene]-1H-isoindol-1-ylidene]acetamide
Sarecycline hydrochloride
C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic D003879 - Dermatologic Agents
5-[6,8-bis(phenylsulfanyl)-1H-benzo[cd]indol-2-ylidene]-1,3-dimethyl-1,3-diazinane-2,4,6-trione
COPPER(II) 3,5-DIISOPROPYLSALICYLATE HYDRATE
C26H36CuO7 (523.1756895999999)
Sitagliptin phosphate monohydrate
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
Idoxifene
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Ibiglustat L-malate
C471 - Enzyme Inhibitor Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
1,1,3,3-Tetraethyl-5,5,6,6-tetrachloroimidacarbocyanine
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes D004396 - Coloring Agents > D002232 - Carbocyanines
(6R,7R)-3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(10R)-6-carboxy-10-[(9R)-4,5-dihydroxy-2-(hydroxymethyl)-10-oxo-9H-anthracen-9-yl]-8-hydroxy-9-oxo-10H-anthracen-1-olate
3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
N-[3-[3-(1-piperidinylsulfonyl)anilino]-2-quinoxalinyl]benzenesulfonamide
C25H25N5O4S2 (523.1347890000001)
N-[2-chloro-5-(4-morpholinylsulfonyl)phenyl]-2-oxo-2-(2-phenyl-3-indolizinyl)acetamide
2-Phenyl-4-quinolinecarboxylic acid [2-[2-chloro-5-(dimethylsulfamoyl)anilino]-2-oxoethyl] ester
[2-(4-Naphthalen-2-ylsulfonylpiperazin-1-yl)-2-oxoethyl] 2-[(3,5-dimethylbenzoyl)amino]acetate
N-(2,6-dichlorobenzoyl)-3-[6-(2,6-dimethoxyphenyl)-2-naphthyl]alanine
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
5-chloro-N-[(2R)-2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]-2-hydroxypropyl]-2-methoxybenzamide
C24H30ClN3O6S (523.1543750000001)
Ninerafaxstat (trihydrochloride)
Ninerafaxstat (IMB-1018972) trihydrochloride is a novel mitotropic agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat trihydrochloride can be used for the research of cardiovascular diseases[1].
(e,2z)-2-{[(2s)-2-amino-3-(3,4-dihydroxyphenyl)-1-hydroxypropylidene]amino}-n-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-3-(3,4,5-trihydroxyphenyl)prop-2-enimidic acid
5,6-dichloro-2-[(1e)-3-(5,6-dichloro-1,3-diethyl-1,3-benzodiazol-2-ylidene)prop-1-en-1-yl]-1,3-diethyl-2h-1,3-benzodiazol-2-yl
19-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione
[(3s,4r,5s)-5-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[4-(hydroxymethyl)phenoxy]oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl pyridine-2-carboxylate
[(10-methanesulfonyl-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}decylidene)amino]oxysulfonic acid
(3s,6s)-19-{[(2s,4r,5r,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione
methyl 4-hydroxy-8-(hydroxymethyl)-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3h-pyrrolo[3,2-e]indole-2-carboxylate
[(z)-(10-methanesulfonyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}decylidene)amino]oxysulfonic acid
6,20-difluoro-14-hydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)
(3s,6r)-19-{[(2s,4r,5r,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione
7,19-difluoro-14-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)
[(3s,4r,5s)-5-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[4-(hydroxymethyl)phenoxy]oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl pyridine-3-carboxylate
2-amino-3-(3,4-dihydroxyphenyl)-n-(1-{[2-(3,4-dihydroxyphenyl)ethenyl]carbamoyl}-2-(3,4,5-trihydroxyphenyl)eth-1-en-1-yl)propanimidic acid
methyl (2r)-4-hydroxy-8-(hydroxymethyl)-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3h-pyrrolo[3,2-e]indole-2-carboxylate
6,20-difluoro-14-hydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)
7,19-difluoro-14-hydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),13,17(22),18,20-decaen-12-one
C26H19F2N3O7 (523.1191008000001)